Scarica l'app Stockscreener
5.11
1.19%
0.06
Dopo l'orario di chiusura:
4.95
-0.16
-3.13%
Precedente Chiudi:
$5.05
Aprire:
$5.16
Volume 24 ore:
193.29K
Relative Volume:
2.10
Capitalizzazione di mercato:
$435.70M
Reddito:
-
Utile/perdita netta:
$-29.64M
Rapporto P/E:
-11.88
EPS:
-0.43
Flusso di cassa netto:
$-39.43M
1 W Prestazione:
+31.36%
1M Prestazione:
+37.59%
6M Prestazione:
+68.71%
1 anno Prestazione:
+66.45%
Intervallo 1D:
$4.65
$5.1799
Intervallo di 1 settimana:
$3.98
$5.1799
Portata 52W:
$2.30
$5.1799
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Nome
Alpha Tau Medical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta DRTS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
5.11 | 430.58M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-04-24 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Iniziato | Piper Sandler | Overweight |
| 2022-04-04 | Iniziato | Citigroup | Buy |
Alpha Tau Medical Ltd Borsa (DRTS) Ultime notizie
Alpha Tau Medical’s Innovative Prostate Cancer Therapy: Study Completion Update - TipRanks
Alpha Tau Medical up sharply as brain cancer trial beginsGlobes - Globes - Israel Business News
Alpha Tau treats first US patient with Alpha DaRT for glioblastoma - MSN
Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly? - simplywall.st
Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau Medical (NASDAQ:DRTS) Price Target Lowered to $7.00 at Citigroup - Defense World
What's Next For Alpha Tau: Major Milestones Expected Through Early 2026 - RTTNews
Alpha Tau Medical (NASDAQ:DRTS) Given New $7.00 Price Target at Citigroup - MarketBeat
Taking on analysts’ expectations and winning: Alpha Tau Medical Ltd (DRTS) - setenews.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock By Investing.com - Investing.com Canada
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock - Investing.com
Promising Clinical Developments and Innovative Technology Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau price target lowered to $7 from $8 at Citi - TipRanks
Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough - Nasdaq
Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading? - Benzinga
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma - Imaging Technology News
Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University - marketscreener.com
Alpha Tau announces first patient treated in study using Alpha DaRT tech - TipRanks
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - The Manila Times
Alpha Tau Medical (NASDAQ:DRTSW) Trading 6.9% Higher – Here’s What Happened - Defense World
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform international peersMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Is Alpha Tau Medical Ltd. Equity Warrant stock a smart buy before Fed meeting2025 Technical Overview & Reliable Breakout Forecasts - Newser
Why Alpha Tau Medical Ltd. Equity Warrant stock is popular among millennialsMarket Risk Analysis & Low Risk Investment Opportunities - Newser
Will Alpha Tau Medical Ltd. stock rally after Fed decisionsJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - TipRanks
Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium - TipRanks
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - The Manila Times
Alpha Tau Announces Presentation of Two Alpha DaRT - GlobeNewswire
Alpha Tau Medical to present pancreatic cancer research at 2026 ASCO symposium - MSN
How Alpha Tau Medical Ltd. stock benefits from global expansionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Alpha Tau Medical Ltd. Receives FDA Approval to Initiate A Trial for Patients with Locally Recurrent Prostate Cancer - marketscreener.com
Alpha Tau receives FDA approval to initiate a trial for patients with locally recurrent prostate cancer - marketscreener.com
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Trial - TipRanks
Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - The Manila Times
Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer - Stock Titan
Alpha Tau to Participate in December Investor Conferences - The Manila Times
COO Gat Files To Sell 16,000 Of Alpha Tau Medical Ltd [DRTS] - TradingView
What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Momentum & Safe Capital Growth Stock Tips - moha.gov.vn
HC Wainwright Has Negative Outlook for DRTS FY2025 Earnings - MarketBeat
What is HC Wainwright’s Forecast for DRTS FY2025 Earnings? - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Reports Q3 2025 Progress and Financials - MSN
Alpha Tau reports Q3 EPS (32c), consensus (12c) - MSN
Alpha Tau Eyes Year-End Japanese Clearance For Alpha DaRT Treatment In Recurrent Head & Neck Cancer - Nasdaq
Alpha Tau Medical Reports Q3 2025 Results and Advances in Cancer Therapy - TipRanks
Alpha Tau Medical Ltd Azioni (DRTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):